BCI Pioneer Teams with Monitoring Firm to Target ALS
One of the earliest researchers to explore therapeutic applications of implanted brain-computer interfaces, Phil Kennedy, founder of Neural Signals, Inc., announced that his firm has entered into a joint-venture relationship to market a BCI system. The new firm, called Neural Logistics LLC, is joint venture between Neural Signals and a public firm called DarkPulse, Inc. Neural Logistics is seeking…
The Government is Here to Help
It’s fashionable these days for business leaders to decry the role of government in their industry, and to be sure, there are many in the neurotechnology industry who could point to seemingly senseless regulatory decisions and policies that have been harmful to growth. But there can be no denying that the U.S. neurotechnology industry has also been the recipient of government largess over the years, when you consider the amount of funding that has been available from agencies such as the NIH, DARPA, and the VA.
Neural Engineers Convene for NIH BRAIN Initiative Meeting
The National Institutes of Health held the 9th Annual BRAIN Initiative Meeting in Bethesda, MD earlier this month. The hybrid meeting was the first to welcome in-person attendance since before the pandemic. Eager researchers and enthusiasts alike grabbed the limited number of spots for in person attendance causing the organizers to put people on a waiting list while they arranged for additional space at the meeting site.
GE Team Reports FUS Effective for Type 2 Diabetes
In the evolving landscape of medical advancements, an emerging field of interest is the use of ultrasound technology for therapeutic neuromodulation. The application of ultrasound to modulate the function of peripheral nerve pathways is called peripheral focused ultrasound stimulation and is becoming a potential tool in the management of chronic diseases. A recent study by a team at GE Research, di…
Neurotech Reports Plans Commercialization Workshop for July 27
Neurotech Reports, the publisher of this newsletter, announced that the fourth annual Neurotech Commercialization Workshop will take place on July 27, 2023. The one-day event will take place on-line using the Zoom platform. The workshop will feature tutorial and interactive sessions with Neurotech Reports editors James Cavuoto, Jeremy Koff, and Jo Jo Platt. The morning agenda, free to advanced regi…
UCLA Team Explores Novel tDCS Therapy for Treating Stroke
In recent months, an number of firms in the neurorehabilitation space have offered new therapies helping stroke patients recover. But while there has been significant activity in the neurovascular space, there have been few neuromodulation approaches to treating the cerebrovascular causes of stroke. About 20 years ago, a California firm called PhotoThera sought to market a laser stimulation system that delivered pulses of near-infrared laser energy through the skull to selected portions of the brain.
The Neurodata Divide
Long-time readers of this publication will recall that we have frequently approached the subjects of ethics in neurotechnology and protecting users’ privacy. Particularly in this space, we have long advocated for “neuro vigilance” against potential threats posed -computer interfaces and deep-brain stimulation. And as NBR senior contributing editor JoJo Platt points out in her coverage of the recent…
UCSF Researchers Uncover Brain Biomarkers for Pain
One of the greatest challenges confronting pain clinicians and healthcare firms targeting chronic pain has been the lack of an objective measure of pain intensity. Although subjective tests such as the VAS score are available to patients and pain doctors, there could be wide variability in the perceived level of pain among different subjects and at different times. This situation not only makes it…
Vendors and Researchers Make Progress with Glioblastoma
Glioblastoma, the deadly brain cancer that impacts about 12,000 people in the U.S. each year, remains one of the most significant unmet medical needs facing the healthcare industry. The five-year survival rate is under 10% and patients survive an average of 15 to 18 months after diagnosis. Recently, several emerging bioelectronic medicine firms and research teams have reported progress at developing therapies for glioblastoma, though there is still a long road ahead for these efforts.
Entrepreneurs Join Academics at Bioelectronic Medicine Forum
About 80 professionals from the Bioelectronic Medicine industry attended the sixth annual Bioelectronic Medicine Forum, held in New York City earlier this month. The event, produced , was held at the New York Academy of Medicine in Manhattan, with some participants joining via Zoom. The full-day conference featured several panel discussions on topics related to bioelectronic medicine, as well as presentations from 10 startup firms in the space.